AI drug creation company

AI药物创造公司

Absci Corporation

Absci公司

ABSI

ABSI

shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with

周三上市前，该公司与

Advanced Micro Devices Inc

超微

AMD

AMD公司

to enhance its

增强其

AI drug discovery capabilities

AI药物发现能力

.

.

The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models.

该合作关系将利用AMD Institute加速器和ROCm软件来支持Absci的先进从头抗体设计模型。

The deal also includes a $20 million private investment in public equity (PIPE) by AMD, underscoring the rising demand for AI applications in the pharmaceutical industry.

该交易还包括AMD对公共股本（PIPE）的2000万美元私人投资，突显出制药行业对人工智能应用的需求不断上升。

Absci

Absci

aims to transform biologics development by utilizing optimized AI solutions that improve biological modeling. The partnership is expected to reduce infrastructure costs while accelerating innovation cycles.

旨在通过利用改进生物建模的优化AI解决方案来改变生物制剂的开发。预计该合作关系将降低基础设施成本，同时加快创新周期。

Also Read:

另请阅读：

Uber And NVIDIA Partner On AI Technology For Autonomous Cars

优步和英伟达合作开发自动驾驶汽车的人工智能技术

AMD’s support will enable Absci to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.

AMD的支持将使Absci能够增强其专有的抗体设计模型IgDesign1，这是第一个经过体外验证的抗体设计反向折叠模型。

Sean McClain

肖恩·麦克莱恩

, Absci’s Founder and CEO, said, “AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery.”

Absci的创始人兼首席执行官表示：“AMD高性能计算机将使我们能够进一步开发下一代抗体治疗剂，我们对这种合作关系在加速药物发现未来方面的潜力感到兴奋。”

Price Action

价格行动

: ABSI shares are trading higher by 44.3% at $4.46 in premarket at the last check Wednesday.

：在周三的最后一次检查中，ABSI股价在上市前上涨了44.3%，达到4.46美元。

Read Next

阅读下一页

:

:

AMD and Nvidia Overtake Intel in Key Markets, Challenging Its Leadership

AMD和Nvidia在关键市场超越英特尔，挑战其领导地位

Photo via Shutterstock.

照片通过Shutterstock拍摄。

Market News and Data brought to you by Benzinga APIs

Benzinga API为您带来的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

©2025 Benzinga.com。Benzinga不提供投资建议。保留所有权利。